Can Tesla’s Chinese AI Gamble Reverse Its Sales Slump?
Investing
- Tesla’s (TSLA) sales in China fell 11.7% in Q2, while Chinese EV makers like BYD and Geely saw growth.
» Read more about: Can Tesla’s Chinese AI Gamble Reverse Its Sales Slump? »
Read MoreCardano Price Forecast: ADA eyes recovery as bullish momentum builds
- Cardano price hovers around $0.92 on Monday after rebounding from its key support at $0.84 last week.
- Derivatives and on-chain data show rising Open Interest and stablecoin market capitalization, hinting at improving sentiment.
- Technical indicators point to bearish exhaustion, suggesting room for an upside rally.
» Read more about: Cardano Price Forecast: ADA eyes recovery as bullish momentum builds »
Read MoreTesla (TSLA) Offers 40% Leasing Discounts to Bolster Europe Sales
Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!
AI is eating the world—and the machines behind it are ravenous.
Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy.
» Read more about: Tesla (TSLA) Offers 40% Leasing Discounts to Bolster Europe Sales »
Read MoreWall Street’s September Fed rate cut bets still hinge on economic data
JavaScript is disabled in your browser.
Please enable JavaScript to proceed.
A required part of this site couldn’t load. This may be due to a browser
extension, network issues, or browser settings. Please check your
connection,
» Read more about: Wall Street’s September Fed rate cut bets still hinge on economic data »
Read MoreSuze Orman Bets On This 'Controversial' Tech Stock—Explains How Her Biggest Investment Blunder Cost Her 'Extraordinary' Gains
Suze Orman, the renowned personal finance expert, has recently shared her top stock picks, her take on cryptocurrencies, and her biggest investing mistake in a recent interview.
Orman Backs Tech Giants, Eyes S&P 500 Above 7,000
Orman in an interview with MarketWatch,
The Burst
Billionaire Buys Stake In Gene Therapy Stock
Ultragenyx may not have crossed your radar but it’s already in billionaire Stan Druckenmiller’s portfolio. What has he spotted in this novel therapies for rare and ultra-rare genetic diseases firm that convinced him to take a position?
Its focus on underserved patient populations, deep pipeline of innovative products, and strong track record in obtaining regulatory approvals make it an attractive long-term investment,
» Read more about: Billionaire Buys Stake In Gene Therapy Stock »
Read MoreThe Ivy
Sleeper IPO Making Comeback, Why Smart Money Is Watching BROS Closely
When Dutch Bros (BROS) IPO’d in 2021, it did so into the teeth of a bear market at a time when risk appetite was shrinking and new issues struggled to hold gains.
Fast-forward to 2025, and we’re starting to see signs that BROS is staging a quiet comeback,
» Read more about: Sleeper IPO Making Comeback, Why Smart Money Is Watching BROS Closely »
Read MoreThe Spotlight
1 FinTech Firm with 30.6% Upside
When you study business for a while, certain metrics just turn out to be much more important than others. The cost to acquire customers is a key focus for many new business owners but their retention is what those who have been around the block focus on.
If you can acquire customers at the same price as the competition but sell them into many other products and services,